These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 37787146)

  • 1. Longitudinal associations of serum biomarkers with early cognitive, amyloid and grey matter changes.
    De Meyer S; Blujdea ER; Schaeverbeke J; Reinartz M; Luckett ES; Adamczuk K; Van Laere K; Dupont P; Teunissen CE; Vandenberghe R; Poesen K
    Brain; 2024 Mar; 147(3):936-948. PubMed ID: 37787146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
    Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
    Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline.
    Dark HE; An Y; Duggan MR; Joynes C; Davatzikos C; Erus G; Lewis A; Moghekar AR; Resnick SM; Walker KA
    Alzheimers Res Ther; 2024 Apr; 16(1):94. PubMed ID: 38689358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting Longitudinal Cognitive Decline and Alzheimer's Conversion in Mild Cognitive Impairment Patients Based on Plasma Biomarkers.
    Park MK; Ahn J; Kim YJ; Lee JW; Lee JC; Hwang SJ; Kim KC
    Cells; 2024 Jun; 13(13):. PubMed ID: 38994939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood Phosphorylated Tau 181 as a Biomarker for Amyloid Burden on Brain PET in Cognitively Healthy Adults.
    McGrath ER; Beiser AS; O'Donnell A; Yang Q; Ghosh S; Gonzales MM; Himali JJ; Satizabal CL; Johnson KA; Tracy RP; Seshadri S
    J Alzheimers Dis; 2022; 87(4):1517-1526. PubMed ID: 35491781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of plasma amyloid beta
    Verberk IMW; Thijssen E; Koelewijn J; Mauroo K; Vanbrabant J; de Wilde A; Zwan MD; Verfaillie SCJ; Ossenkoppele R; Barkhof F; van Berckel BNM; Scheltens P; van der Flier WM; Stoops E; Vanderstichele HM; Teunissen CE
    Alzheimers Res Ther; 2020 Sep; 12(1):118. PubMed ID: 32988409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological mechanisms of resilience to tau pathology in Alzheimer's disease.
    Svenningsson AL; Bocancea DI; Stomrud E; van Loenhoud A; Barkhof F; Mattsson-Carlgren N; Palmqvist S; Hansson O; Ossenkoppele R
    Alzheimers Res Ther; 2024 Oct; 16(1):221. PubMed ID: 39396028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly.
    Koivumäki M; Ekblad L; Lantero-Rodriguez J; Ashton NJ; Karikari TK; Helin S; Parkkola R; Lötjönen J; Zetterberg H; Blennow K; Rinne JO; Snellman A
    Alzheimers Res Ther; 2024 May; 16(1):112. PubMed ID: 38762725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal blood biomarker trajectories in preclinical Alzheimer's disease.
    Yakoub Y; Ashton NJ; Strikwerda-Brown C; Montoliu-Gaya L; Karikari TK; Kac PR; Gonzalez-Ortiz F; Gallego-Rudolf J; Meyer PF; St-Onge F; Schöll M; Soucy JP; Breitner JCS; Zetterberg H; Blennow K; Poirier J; Villeneuve S;
    Alzheimers Dement; 2023 Dec; 19(12):5620-5631. PubMed ID: 37294682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathologic and cognitive correlates of plasma biomarkers in neurodegenerative disease.
    Cousins KAQ; Phillips JS; Das SR; O'Brien K; Tropea TF; Chen-Plotkin A; Shaw LM; Nasrallah IM; Mechanic-Hamilton D; McMillan CT; Irwin DJ; Lee EB; Wolk DA
    Alzheimers Dement; 2024 Jun; 20(6):3889-3905. PubMed ID: 38644682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients.
    Mendes AJ; Ribaldi F; Lathuiliere A; Ashton NJ; Zetterberg H; Abramowicz M; Scheffler M; Assal F; Garibotto V; Blennow K; Frisoni GB
    Alzheimers Res Ther; 2024 May; 16(1):110. PubMed ID: 38755703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and biological relevance of glial fibrillary acidic protein in Alzheimer's disease.
    Yang Z; Sreenivasan K; Toledano Strom EN; Osse AML; Pasia LG; Cosme CG; Mugosa MRN; Chevalier EL; Ritter A; Miller JB; Cordes D; Cummings JL; Kinney JW
    Alzheimers Res Ther; 2023 Nov; 15(1):190. PubMed ID: 37924152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease.
    Pereira JB; Janelidze S; Smith R; Mattsson-Carlgren N; Palmqvist S; Teunissen CE; Zetterberg H; Stomrud E; Ashton NJ; Blennow K; Hansson O
    Brain; 2021 Dec; 144(11):3505-3516. PubMed ID: 34259835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers.
    Janelidze S; Christian BT; Price J; Laymon C; Schupf N; Klunk WE; Lott I; Silverman W; Rosas HD; Zaman S; Mapstone M; Lai F; Ances BM; Handen BL; Hansson O
    JAMA Neurol; 2022 Aug; 79(8):797-807. PubMed ID: 35789365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer's Disease Continuum.
    Coomans EM; Verberk IMW; Ossenkoppele R; Verfaillie SCJ; Visser D; Gouda M; Tuncel H; Wolters EE; Timmers T; Windhorst AD; Golla SSV; Scheltens P; van WM; Flier D; van Berckel BNM; Teunissen CE
    J Nucl Med; 2023 Mar; 64(3):437-443. PubMed ID: 36229187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Astrocyte reactivity is associated with tau tangle load and cortical thinning in Alzheimer's disease.
    Guo T; Li A; Sun P; He Z; Cai Y; Lan G; Liu L; Li J; Yang J; Zhu Y; Zhao R; Chen X; Shi D; Liu Z; Wang Q; Xu L; Zhou L; Ran P; Wang X; Sun K; Lu J; Han Y
    Mol Neurodegener; 2024 Jul; 19(1):58. PubMed ID: 39080744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measures of cortical microstructure are linked to amyloid pathology in Alzheimer's disease.
    Spotorno N; Strandberg O; Vis G; Stomrud E; Nilsson M; Hansson O
    Brain; 2023 Apr; 146(4):1602-1614. PubMed ID: 36130332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers.
    Mattsson-Carlgren N; Salvadó G; Ashton NJ; Tideman P; Stomrud E; Zetterberg H; Ossenkoppele R; Betthauser TJ; Cody KA; Jonaitis EM; Langhough R; Palmqvist S; Blennow K; Janelidze S; Johnson SC; Hansson O
    JAMA Neurol; 2023 Apr; 80(4):360-369. PubMed ID: 36745413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression.
    Rabl M; Zullo L; Lewczuk P; Kornhuber J; Karikari TK; Blennow K; Zetterberg H; Bavato F; Quednow BB; Seifritz E; von Gunten A; Clark C; Popp J
    Alzheimers Res Ther; 2024 Jul; 16(1):165. PubMed ID: 39054505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.